American Journal of Cardiology
Volume 102, Issue 5, Supplement , Pages 29G-37G , 8 September 2008

Device Therapies in the Post-Myocardial Infarction Patient with Left Ventricular Dysfunction

  • Alan H. Kadish, MD

      Affiliations

    • Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    • Corresponding Author InformationAddress for reprints: Alan H. Kadish, MD, Division of Cardiology, Northwestern University Feinberg School of Medicine, 201 East Huron Street, Galter 10-240, Chicago, Illinois 60611
    • ,
  • James A. Reiffel, MD

      Affiliations

    • Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, New York, USA
    • ,
  • Gerald V. Naccarelli, MD

      Affiliations

    • Division of Cardiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
    • ,
  • John P. DiMarco, MD, PhD

      Affiliations

    • Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, Virginia, USA

References 

  1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  2. Narang R, Cleland JG, Erhardt L, Ball SG, Coats AJS, Cowley AJ, et al. Mode of death in chronic heart failure: a request and proposition for more accurate classification. Eur Heart J. 1996;17:1390–1403
  3. Lanza GA, Guido V, Galeazzi MM, Mustilli M, Natali R, Ierardi C, et al. Prognostic role of heart rate variability in patients with a recent acute myocardial infarction. Am J Cardiol. 1998;82:1323–1328
  4. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350:1417–1424
  5. Centers for Medicare & Medicaid Services. Decision memo for implantable defibrillators. Available at: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=148&.
  6. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  7. Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2329–2334
  8. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  9. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol. 2004;43:1459–1465
  10. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  11. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940
  12. Naccarelli GV. Post myocardial infarction, left ventricular dysfunction, and the expanding role of cardiac implantable electrical devices. Clin Cardiol. 2005;28(suppl 1):I-51–I-57
  13. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation. 1992;85(suppl):I2–I10
  14. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol. 2005;28(suppl 1):I3–I11
  15. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation. 2004;109:2685–2691
  16. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol. 2001;38:1902–1911
  17. Gold MR, Spencer W. T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2003;18:1–5
  18. Hohnloser SH, Ikeda T, Bloomfield DM, Dabbous OH, Cohen RJ. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet. 2003;362:125–126
  19. Bloomfield DM, Steinman RC, Namerow PB, Parides M, Davidenko J, Kaufman ES, et al Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation. 2004;110:1885–1889
  20. Hohnloser SH, Klingenheben T, Bloomfield D, Dabbous O, Cohen RJ. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. J Am Coll Cardiol. 2003;41:2220–2224
  21. Rashba EJ, Osman AF, MacMurdy K, Kirk MM, Sarang S, Peters RW, et al. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002;13:770–775
  22. Bloomfield DM, Bigger JT, Steinman RC, Namerow PB, Parides MK, Curtis AB, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006;47:456–463
  23. Costantini O, Rosenbaum DS, Hohnloser SH, Kirk M, Lerman B, Baker JII, et al. The Alternans Before Cardioverter Defibrillator trial: a noninvasive strategy for primary prevention of sudden cardiac death using MTWA [abstract]. Circulation. 2006;114:2426
  24. Kusmirek SL, Gold MR. Dynamic changes of T-wave alternans: does it predict short-term arrhythmia vulnerability [abstract]?. J Cardiovasc Electrophysiol. 2007;18:518–519
  25. Stecker EC, Zargarian M, Dogra V, John BT, Kron J, McAnulty JH, et al. Native QRS duration predicts the occurrence of arrhythmic events in ICD recipients. Europace. 2006;8:859–862
  26. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol. 2005;46:2183–2192
  27. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet. 1998;351:478–484
  28. Rashba EJ, Estes NA, Wang P, Schaechter A, Howard A, Zareba W, et al. Preserved heart rate variability identifies low-risk patients with nonischemic dilated cardiomyopathy: results from the DEFINITE trial. Heart Rhythm. 2006;3:281–286
  29. Curtis AB, Bigger JT, DiMarco JP, Anderson JL The CABG Patch Trial Investigators. Epicardial cardioverter-defibrillators do not cause postoperative arrhythmias. Am J Cardiol. 1998;82:1114–1117A9
  30. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  31. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol. 2006;48:e247–e346
  32. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235
  33. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82–e292
  34. Voigt A, Ezzeddine R, Barrington W, Obiaha-Ngwu O, Ganz LI, London B, et al. Utilization of implantable cardioverter-defibrillators in survivors of cardiac arrest in the United States from 1996 to 2001. J Am Coll Cardiol. 2004;44:855–858
  35. Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP, et al Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–2158
  36. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–1890
  37. Zareba W, Moss AJ. Noninvasive risk stratification in postinfarction patients with severe left ventricular dysfunction and methodology of the MADIT II noninvasive electrocardiology substudy. J Electrocardiol. 2003;(36 Suppl):101–108
  38. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288:3115–3123
  39. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583
  40. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667–674
  41. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7–12
  42. Yap YG, Duong T, Bland M, Malik M, Torp-Pedersen C, Køber L, et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J. 2005;26:1385–1393
  43. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–2588
  44. Gehi A, Haas D, Fuster V. Primary prophylaxis with the implantable cardioverter-defibrillator: the need for improved risk stratification. JAMA. 2005;294:958–960
  45. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–2937
  46. Best PJ, Hayes DL, Stanton MS. The potential usage of dual chamber pacing in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 1999;22:79–85
  47. Stambler BS, Ellenbogen KA, Orav EJ, Sgarbossa EB, Estes NAM, Rizo-Patron C, et al. Predictors and clinical impact of atrial fibrillation after pacemaker implantation in elderly patients treated with dual chamber versus ventricular pacing. Pacing Clin Electrophysiol. 2003;26:2000–2007
  48. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA. 2006;295:809–818
  49. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM EMPIRIC Trial Investigators. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006;48:330–339
  50. Swerdlow CD, Friedman PA. Advanced ICD troubleshooting: Part II. Pacing Clin Electrophysiol. 2006;29:70–79
  51. Goldberger JJ, Horvath G, Inbar S, Kadish AH. Utility of predischarge and one-month transvenous implantable defibrillator tests. Am J Cardiol. 1997;79:822–826
  52. Louis AA, Turner T, Gretton M, Baksh A, Cleland JG. A systematic review of telemonitoring for the management of heart failure. Eur J Heart Fail. 2003;5:583–590
  53. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977–982
  54. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–677
  55. Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation. 2003;108:2596–2603
  56. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–2868
  57. Bax JJ, Ansalone G, Breithardt OA, Derumeaux G, Leclercq C, Schalij M, et al. Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use? (A critical appraisal). J Am Coll Cardiol. 2004;44:1–9
  58. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol. 2002;40:1615–1622
  59. Ansalone G, Giannantoni P, Ricci R, Trambaiolo P, Fedele F, Santini M. Doppler myocardial imaging to evaluate the effectiveness of pacing sites in patients receiving biventricular pacing. J Am Coll Cardiol. 2002;39:489–499
  60. Yu CM, Bax JJ, Monaghan M, Nihoyannopoulos P. Echocardiographic evaluation of cardiac dyssynchrony for predicting a favourable response to cardiac resynchronisation therapy. Heart. 2004;90:vi17–vi22
  61. Worley SJ, Gohn DC, Smith TM. Optimization of cardiac resynchronization: left atrial electrograms measured at implant eliminates the need for echo and identifies patients where AV optimization is not possible [abstract]. J Card Fail. 2004;10:S62
  62. Koglek W, Kranig W, Kowalski M, Kronski D, Brandl J, Oberbichler A, et al. Eine einfache Methode zur Bestimmung des AV-Intervalls bei Zweikammerschrittmachern. Herzschrittmacherther Elektrophysiol. 2000;11:244–253
  63. Trupp RJ. Cardiac resynchronization therapy: a practical guide for device optimization, part I. Congest Heart Fail. 2006;12:169–173
  64. Donal E, Leclercq C, Linde C, Daubert JC. Effects of cardiac resynchronization therapy on disease progression in chronic heart failure. Eur Heart J. 2006;27:1018–1025
  65. Trupp RJ. Cardiac resynchronization therapy: a practical guide for patient management after device implantation, part II. Congest Heart Fail. 2006;12:219–222

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00998-3

doi: 10.1016/j.amjcard.2008.06.008

American Journal of Cardiology
Volume 102, Issue 5, Supplement , Pages 29G-37G , 8 September 2008

Article Tools